Stryker Co. (NYSE:SYK) Shares Sold by Community Bank N.A.

Community Bank N.A. lowered its position in shares of Stryker Co. (NYSE:SYK) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,293 shares of the medical technology company’s stock after selling 267 shares during the period. Community Bank N.A.’s holdings in Stryker were worth $1,884,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Farmers & Merchants Trust Co of Chambersburg PA grew its holdings in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. HBC Financial Services PLLC acquired a new stake in shares of Stryker in the 4th quarter worth approximately $37,000. Bourgeon Capital Management LLC acquired a new stake in shares of Stryker in the 4th quarter worth approximately $37,000. Operose Advisors LLC grew its holdings in shares of Stryker by 308.6% in the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 108 shares during the period. Finally, Venturi Wealth Management LLC grew its holdings in shares of Stryker by 97.1% in the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after acquiring an additional 67 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.6 %

Shares of SYK traded up $1.94 during trading hours on Wednesday, hitting $336.85. The stock had a trading volume of 1,478,179 shares, compared to its average volume of 1,282,265. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The firm has a market cap of $128.16 billion, a P/E ratio of 40.83, a P/E/G ratio of 2.64 and a beta of 0.89. The company’s fifty day simple moving average is $349.39 and its 200 day simple moving average is $314.24. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period last year, the company posted $3.00 EPS. Equities research analysts forecast that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 212,109 shares of company stock valued at $72,845,768. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wells Fargo & Company increased their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Truist Financial increased their target price on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st. Roth Mkm increased their target price on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Citigroup increased their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.